Thank you to our speakers, sponsors, and delegates who joined us at the 2nd Molecular Glue Drug Development Summit!

If you are interested in the 2025 meeting, please get in touch at info@hansonwade.com

Accelerate the Discovery, Validation and Clinical Translation of Novel and Rationally Designed Molecular Glues through Systematic Screening, Expanding Ligase Toolbox and Optimizing Pharmacological Properties

The 2nd Molecular Glue Drug Development Summit 2024

Uniting Large Pharma, Innovative Biotech & Leading Academics Dedicated to Accelerating the Next-Generation of Molecular Glues into the Clinic

Molecular glue development continues to gain exponential momentum, with advances in screening tools, identification assays and structure-based design. With numerous strategic collaborations and investments into rationale drug discovery, the molecular glue field is propelling the clinical progression of next-generation molecular glue candidates across a spectrum of indications and undruggable targets.

Owing to this, the 2nd Molecular Glue Drug Development Summit returned as the world’s only fully molecular glue-dedicated meeting. The conference united 80+ glue experts devoted to accelerating the discovery and development of novel, rationally designed and therapeutically validated glues for patients in need.

What Was New to the 2024 Content:

Molecular Glue Drug Development Summit

Extensive content covering the latest advances in rational glue screening, biochemical optimization and progressing the wave of next-generation molecular glues into pre-clinical and clinical settings.

Molecular Glue Drug Development Summit

A new cohort of expert speakers and companies presenting from the likes of Neomorph, GSK, Lyterian Therapeutics & Gandeeva Therapeutics

Molecular Glue Drug Development Summit

An expert-led pre-conference workshop day addressing hurdles across the molecular glue development pipeline including artificial intelligence, the proteomics workflow and best pre-clinical and IND filing practices to accelerate translation and development of novel molecular glues for patients.

2024 Expert Speakers Included:

2nd Molecular Glue Drug Development Summit
2nd Molecular Glue Drug Development Summit
2nd Molecular Glue Drug Development Summit

Christian Ottmann
Founder & Chief
Technology Officer
Ambagon
Therapeutics

Ingrid Wertz
Chief Executive
Officer & Co-Founder
Lyterian
Therapeutics

Lena Dolgikh
Head of Computer-
Aided Drug Design
Monte Rosa
Therapeutics

2nd Molecular Glue Drug Development Summit
40974 - Jason Crawford - Gandeeva
2nd Molecular Glue Drug Development Summit

Patrick Arsenault
Director- Lead
Discovery
Triana Biomedicines

Jason Crawford
Senior Vice President
Drug Discovery
Gandeeva Therapeutics

Shanique Alabi
Principal Investigator
GSK

2024 Attending Companies Included:

2nd Molecular Glue Drug Development Summit

2024 Partners:

Expertise Partners

2nd Molecular Glues Drug Development Summit - Promega Logo
Certara-Appliedbiomath_Vertical logo - 2024 Partner

Event Partners

Biortus Png

Industry Partners

40974 - Rapafusyn - logo
Other Events in the Small Molecules & TPD World Series: